NCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
Clinical Trials
12 trialsNCT05969821 2026-03-23
CHIS
Assistance Publique - HĂ´pitaux de Paris
Not yet recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT05186753 2026-03-04
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cogent Biosciences, Inc.
Phase 2 Active not recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT04996875 2025-05-30
APEX
Cogent Biosciences, Inc.
Phase 2 Recruiting
NCT01667133 2022-06-13
A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
Takeda
Phase 1/2 Completed
NCT01200017 2021-05-27
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
University of California, San Francisco
No longer available
NCT02627573 2019-04-05
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
St. Petersburg State Pavlov Medical University
Phase 2 Terminated
NCT02294552 2018-01-16
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
St. Petersburg State Pavlov Medical University
Phase 2 Completed
NCT00000591 2016-04-15
T-Cell Depletion in Unrelated Donor Marrow Transplantation
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated